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In the course of a screening program for the inhibitors of angiogenesis from marine
sources, AD0157, a pyrrolidinedione fungal metabolite, was selected for its
angiosupressive properties. AD0157 inhibited the growth of endothelial and tumor cells in
culture in the micromolar range. Our results show that subtoxic doses of this compound
inhibit certain functions of endothelial cells, namely, differentiation, migration and
proteolytic capability. Inhibition of the mentioned essential steps of in vitro angiogenesis is
in agreement with the observed antiangiogenic activity, substantiated by using two in vivo
angiogenesis models, the chorioallantoic membrane and the zebrafish embryo
neovascularization assays, and by the ex vivo mouse aortic ring assay. Our data indicate
that AD0157 induces apoptosis in endothelial cells through chromatin condensation, DNA
fragmentation, increases in the subG1 peak and caspase activation. The data shown here
altogether indicate for the first time that AD0157 displays antiangiogenic effects, both in
vitro and in vivo, that are exerted partly by targeting the Akt signaling pathway in activated
endothelial cells. The fact that these effects are carried out at lower concentrations than
those required for other inhibitors of angiogenesis makes AD0157 a new promising drug
candidate for further evaluation in the treatment of cancer and other angiogenesis-related
pathologies. [Our experimental work is supported by grant P12-CTS-1507 (Andalusian
Government and FEDER) and funds from group BIO-267 (Andalusian Government). The
"CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain). This
communication has the support of a travel grant "Universidad de Málaga. Campus de
Excelencia Internacional Andalucía Tech"].
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